2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Nervous System Injury
  5. Traumatic Brain Injury

Traumatic Brain Injury

Traumatic brain injury (TBI) is a type of acquired brain damage caused by external forces such as blows, jolts, or penetrating injuries to the head, resulting in temporary or permanent impairments in cognitive, physical, and psychosocial functions. It is classified by severity—mild (e.g., concussion), moderate, or severe—and can lead to a wide range of outcomes, from minor disabilities with full recovery to long-term impairment or death. Common causes include falls, motor vehicle accidents, and violence, with symptoms varying from headache and confusion to altered consciousness, memory deficits, and behavioral changes. TBI involves both primary injury at the time of impact and secondary injury processes that may develop over time. It remains a leading cause of death and disability in the United States, particularly affecting children and young adults, and requires prompt medical evaluation for proper diagnosis and management.

Traumatic Brain Injury (7):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-50722
    NNC 55-0396 357400-13-6 98.43%
    NNC 55-0396 (NNC 55-0396 dihydrochloride) is a blood-brain-barrier-permeable T-type Ca2+ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 selectively inhibits T-type Ca2+ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma.
    NNC 55-0396
  • HY-N0657
    Pinoresinol Diglucoside 63902-38-5 99.84%
    Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis.
    Pinoresinol Diglucoside
  • HY-11095
    NPS 2390 226878-01-9 99.90%
    NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain.
    NPS 2390
  • HY-P3281
    FGL peptide 499993-62-3 99.69%
    FGL peptide is a fibroblast growth factor receptor (FGFR) modulator and blood-brain barrier-penetrant. FGL peptide activates NCAM-FGFR and FGFR1 signaling pathways. FGL peptide alters expression of apoptosis, signal transduction and metabolism regulator genes in traumatic brain injury contexts. FGL peptide can be used for the research of traumatic brain injury.
    FGL peptide
  • HY-103344
    ZJ43 723331-20-2 99.6%
    ZJ43 is a NAAG peptidase inhibitor and glutamate carboxypeptidase II/III (GCP II/III) inhibitor with human GCP II IC50 of 2.4 nM and Ki of 0.8 nM. ZJ43 blocks N-acetylaspartylglutamate hydrolysis, elevates extracellular N-acetylaspartylglutamate levels, and activates group II metabotropic glutamate receptors (mGluR). ZJ43 can be used for the research of schizophrenia, inflammatory pain, neuropathic pain, and traumatic brain injury.
    ZJ43
  • HY-183944
    BN80933 214348-10-4
    BN80933 is a selective neuronal nitric oxide synthase (nNOS) inhibitor with a rat Ki of 0.92 μM. BN80933 inhibits lipid peroxidation, and blocks hypoxia-induced lactate dehydrogenase elevation and delayed 8-epiprostaglandin F2α elevation. BN80933 can be used for the research of stroke, and traumatic brain injury.
    BN80933
  • HY-50722B
    NNC 55-0396 free base 357400-14-7
    NNC 55-0396 free base is a blood-brain-barrier-permeable T-type Ca2+ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 free base selectively inhibits T-type Ca2+ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 free base reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 free base inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma.
    NNC 55-0396 free base